Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Retatrutide (LY3437943) is an investigational once-weekly injectable from Eli Lilly that activates three metabolic receptors at once — GLP-1, GIP, and glucagon. In its Phase 2 obesity trial it produced about 24.2% mean body-weight loss at 48 weeks on the top dose [1], and Lilly's first pivotal Phase 3 obesity readout, reported in 2026, pushed further still [4]. It is not approved anywhere, can't be legally compounded, and can't be prescribed outside a clinical trial.
This is a guide to what the trial record actually shows, what the mechanism does, and what the regulatory and gray-market landscape looks like for U.S. readers in mid-2026. The Reddit threads and peptide-vendor sites have been running well ahead of both the data and the law for about three years; the aim here is to be useful to people who have read those threads and want to know which parts are real.
Retatrutide is an investigational synthetic peptide developed by Eli Lilly, internally coded LY3437943 [1]. No brand name exists because no approved product exists. In practice it's a once-weekly subcutaneous injection, and its half-life of roughly six days comes from acylation with a fatty diacid — the same pharmacokinetic trick that bought semaglutide and tirzepatide their weekly dosing.
It's the most clinically advanced triple receptor agonist in the obesity pipeline. Lilly runs it under two Phase 3 program families: TRIUMPH for obesity and its complications (including knee osteoarthritis and obstructive sleep apnea) and TRANSCEND for type 2 diabetes [4][6]. Together these enroll well over 7,000 participants, and the first Phase 3 readouts arrived in late 2025 and early 2026.
Semaglutide hits one receptor (GLP-1R). Tirzepatide hits two (GLP-1R and GIPR). Retatrutide hits three: GLP-1R, GIPR, and GCGR, the glucagon receptor [1]. That third one is where things get interesting, and where the reading has to be careful.
GLP-1R activation does the heavy lifting for the whole class — glucose-dependent insulin secretion, slowed gastric emptying, and hypothalamic satiety signaling that makes people eat less. It's also what drives most of the nausea. GIPR activation augments insulin secretion glucose-dependently and modulates how adipose tissue handles energy; adding GIP to GLP-1 (the tirzepatide design) produces more weight loss than GLP-1 alone, and there's preclinical evidence it may blunt some GLP-1-induced nausea, though that mechanism is still debated.
GCGR activation is the new piece. Glucagon is, in the lay imagination, the hormone that raises blood sugar — seemingly the wrong thing to do in a metabolic drug. But chronic low-grade glucagon-receptor agonism also pushes resting energy expenditure up and strips fat out of the liver, and in this molecular design the hyperglycemic effect is more than offset by co-activating GLP-1R and GIPR. Preclinical work by Coskun and colleagues at Lilly (Cell Metabolism, 2022) described a binding profile with balanced GCGR and GLP-1R activity and more prominent GIPR activity, and documented weight loss persisting 43 days post-dose in obese animals, with energy expenditure rising while intake fell [3]. That combination — output up, intake down — is what predicted the size of effect now showing up in humans.
Three molecules, three receptor profiles, three different weight-loss ceilings in their respective programs. The figures below are not from head-to-head trials; they come from separately conducted studies in overlapping but not identical populations, and should be read with that caveat.
| Agent | Receptors | Reported max weight loss | Trial program |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1R | ~14.9% (STEP-1) | STEP [12] |
| Tirzepatide (Zepbound) | GLP-1R + GIPR | ~20.9% (SURMOUNT-1) | SURMOUNT [11] |
| Retatrutide | GLP-1R + GIPR + GCGR | ~24% Phase 2; higher in Phase 3 topline | TRIUMPH [1][4] |
The mechanistic distinction predicts a different ceiling. GLP-1 monotherapy drives weight loss mainly by suppressing intake; adding GIP gets somewhat more suppression and possibly better tolerability; adding glucagon agonism adds a push on the expenditure side. That's why retatrutide's Phase 2 weight-loss curves had not plateaued at 48 weeks [1], and why the Phase 3 extension data show patients continuing to lose weight into a second year [4].
The trial that put retatrutide on the map was published in the New England Journal of Medicine on June 26, 2023, by Jastreboff and colleagues (NCT04881760) [1]. It enrolled 338 adults, all with BMI ≥30, or 27–30 with at least one weight-related comorbidity, in a 48-week, randomized, double-blind, placebo-controlled Phase 2 study; people with type 2 diabetes were excluded. A parallel Phase 2 trial in type 2 diabetes landed the same week in the Lancet, from Rosenstock and colleagues [2]. Doses ran 1, 4, 8, and 12 mg once weekly, with stepwise titration into the higher-dose arms, against placebo.
At 24 weeks the 12 mg arm reached about 17.5% mean body-weight reduction; by week 48 the same arm hit 24.2%, against 2.1% on placebo [1]. Essentially every participant on 8 mg and 12 mg cleared the 5% threshold, and a substantial share of the 12 mg group crossed 30% body-weight reduction — territory that used to belong to bariatric surgery. Secondary endpoints moved the way you'd hope: HbA1c, systolic blood pressure, triglycerides, and liver fat all down. The line that mattered most to the field was that weight loss was dose-dependent and had not plateaued at 48 weeks — meaning the Phase 2 numbers were a floor, not a ceiling.
Phase 3 has so far confirmed that read. TRIUMPH-1 (NCT05929066), a pivotal Phase 3 obesity trial that enrolled 2,335 participants with a high mean BMI and randomized them across retatrutide doses and placebo over an 80-week main period, completed in April 2026 [5]. In Lilly's topline release, the highest doses produced weight loss exceeding the Phase 2 figures, with a pre-specified extension (532 participants with BMI ≥35 who completed the 80-week study) reaching roughly 30% mean reduction at two years on the top maintained dose [4]. The TRANSCEND-T2D-1 readout (NCT06354660), announced March 19, 2026, in 537 medication-naive type 2 diabetics over 40 weeks, reported HbA1c reductions of about 1.7–2.0% across active doses alongside meaningful weight loss [6][7]. As is consistent across the GLP-1 class, the diabetes population lost less weight than the non-diabetic obesity population.
TRIUMPH-4 (NCT05931367), in 445 adults with obesity and knee osteoarthritis, completed in November 2025 [8]. Lilly reported topline results on 11 December 2025: 28.7% mean weight loss at 12 mg and 26.4% at 9 mg over 68 weeks, alongside a 4.5-point (75.8%) reduction in WOMAC knee-pain score, with more than one in eight retatrutide-treated participants free of knee pain at trial end [13]. These are company-reported topline figures; the full results have not yet been peer-reviewed.
The adverse-event profile in Phase 2 looked like a stronger version of what the field has seen with tirzepatide. GI symptoms dominated — nausea (up to roughly 60% at 12 mg), vomiting, diarrhea, constipation — all dose-dependent, mostly mild to moderate, mostly concentrated during titration [1]. Heart rate rose by about 5–7 bpm on average, peaked around week 24, then declined, a pattern broadly consistent with the class. A network meta-analysis found adverse-event frequency higher for retatrutide than tirzepatide (relative risk versus placebo around 4.1 vs 2.8), consistent with the molecule's greater pharmacological reach [10].
The signal worth watching emerged at Phase 3 scale and was not prominent in Phase 2: dysesthesia — tingling or altered skin sensation. In the TRIUMPH-4 topline it occurred in 20.9% of participants at 12 mg and 8.8% at 9 mg, against 0.7% on placebo — and Lilly describes the events as generally mild and rarely a reason to stop treatment [13]. It is not unique to retatrutide: a 2026 pharmacovigilance analysis of VigiBase found paraesthesia and dysesthesia signals across the GLP-1 class, including hyperaesthesia with semaglutide and tirzepatide and burning sensation with semaglutide [14]. What looks distinctive here is the dose-dependence and the size of the gap over placebo, which fits glucagon-receptor agonism as the driver. Worth understanding before the highest dose, not a reason for alarm. The class warnings still apply — thyroid C-cell tumors (rodent only, human relevance unknown), pancreatitis, gallbladder events, severe constipation.
The Phase 3 file rests on two umbrella programs. TRIUMPH covers obesity and its complications: TRIUMPH-1 is the registrational obesity trial, additional TRIUMPH trials cover obesity with cardiovascular disease and other comorbidities, TRIUMPH-4 covers knee osteoarthritis, and basket sub-studies cover obstructive sleep apnea. Total TRIUMPH enrollment exceeds 5,800 participants, with the design described by Giblin and colleagues in Diabetes, Obesity and Metabolism (2026) [9]. TRANSCEND covers type 2 diabetes: the program began in 2024 and has enrolled more than 2,050 participants across three global registrational trials, of which TRANSCEND-T2D-1 (the medication-naive cohort) is the first to read out [6]. Primary endpoints are percent change in body weight (TRIUMPH) and change in HbA1c (TRANSCEND); remaining trials are expected to report through 2026 and into 2027.
This is the section most often misread on social media, so to be exact: retatrutide is not FDA approved. It's not approved by the EMA, the MHRA, or any other major regulator. It's investigational only, and the only legal way for a U.S. patient to receive it is by enrollment in an active Eli Lilly clinical trial [4].
As of mid-2026, no New Drug Application has been publicly confirmed as submitted. The Phase 3 readouts that arrived in late 2025 and early 2026 are topline pre-NDA data. Analyst speculation about approval has clustered around 2027 or 2028, but those are projections; there's no PDUFA date because there's no application on the public record yet. On compounding: retatrutide isn't on the FDA drug-shortage list, and it can't be, because it's not an approved drug. The 503A and 503B pathways don't authorize compounding of unapproved investigational molecules, so any "retatrutide" sold by compounding pharmacies or peptide vendors is operating outside any FDA-recognized authority.
The honest answer is: nothing, outside trial enrollment. ClinicalTrials.gov listings are the only legitimate access route, and recruitment for the largest studies is now substantially closed, though extensions and sub-studies continue [5][8]. The websites selling "retatrutide for research use only," the peptide vendors offering vials at various weights, and the compounding pharmacies advertising the molecule are not operating within any FDA-authorized framework. The buyer-beware concern isn't only legal; it's pharmacological — no verified potency, no sterility certification, no identity assurance a buyer in that market can rely on.
The peptide subreddits have been running well ahead of both the regulatory and clinical record. The pattern, roughly: the community gets the headline right and the extrapolations wrong.
What's right: the Phase 2 and Phase 3 weight-loss numbers are real, the triple-agonist mechanism is real, the drug is more potent than tirzepatide on percent body-weight reduction, and the dose-response curve is steeper than the field assumed possible. What's overstated or unsupported: that gray-market vials are pharmacologically equivalent to the trial drug (they aren't necessarily); that forum self-titration protocols will replicate trial outcomes (they won't necessarily); and that the safety picture is clean (the heart-rate rise is modest and self-limiting, but the dysesthesia signal is real and emerged only at Phase 3 scale). Anecdotal reports of muscle loss circulate without imaging data to support or refute them — the published trials have not reported body-composition endpoints in a form that settles the question. The largest gap between hype and evidence concerns durability: the longest published follow-up runs to about two years, the class as a whole shows large regain after stopping, and whether retatrutide's glucagon component changes that is an empirical question without an answer yet.
The Phase 2 obesity trial took adults 18–75 with BMI ≥30, or 27–30 with a weight-related comorbidity; type 2 diabetes ruled people out, and the mean baseline BMI sat around 37 [1]. TRIUMPH-1 went heavier, with the same comorbidity-or-BMI gating but a higher mean BMI — shifting the study toward severe obesity, where comorbid load stacks and absolute pounds-lost numbers look larger [5]. The diabetes program enrolled a different cohort: TRANSCEND-T2D-1 specifically took medication-naive type 2 diabetics with a mean diabetes duration around 2.5 years [6]. Not enrolled, and therefore unknown: adolescents, pregnant or lactating women, people with low eGFR, and people with a history of pancreatitis or of medullary thyroid carcinoma / MEN-2. Extrapolation beyond the studied population requires caution.
Long-term safety tops the list — two years is the longest published exposure, and the rodent thyroid C-cell finding remains a class warning whose human relevance has never been cleanly resolved. The dysesthesia signal needs a mechanism, a natural history, and dose-response data. Body composition (lean-mass change) needs DEXA/MRI substudies at Phase 3 doses. Bone density after large, rapid weight loss is an open question. The hepatic effects of chronic glucagon-receptor agonism beyond fat reduction aren't fully characterized. Cardiovascular outcomes await the dedicated TRIUMPH CV trial — until that reads out, retatrutide is a weight-loss drug with cardiometabolic biomarker improvements, not yet a proven cardiovascular drug. And there's no published retatrutide discontinuation data, which is the single biggest practical question for a chronic obesity medication.
Retatrutide is the most potent obesity pharmacotherapy that has entered late-stage trials. The weight-loss numbers are unprecedented for a non-surgical intervention, the mechanism is distinct from what came before, and the Phase 3 readouts have so far confirmed and modestly exceeded what Phase 2 predicted. It's also unapproved, unavailable outside a trial, and carries a novel safety signal at the top dose that didn't surface at Phase 2 scale. The 2027–2028 approval timelines are projections, not commitments, and the gray market is not a safe substitute for the trial drug. The right posture for a careful reader in mid-2026 is informed patience: understand what the trial record shows, understand what it doesn't yet show, and wait for the regulatory file to resolve. The drug is coming. It isn't here yet.
No. Retatrutide has no FDA approval and no approved label, and it isn't approved by the EMA or MHRA either. It's investigational, in Phase 3 trials, with no NDA confirmed on the public record as of mid-2026 [4].
Across separate (not head-to-head) trials, retatrutide's Phase 2 produced ~24% at 48 weeks, tirzepatide ~20.9% at 72 weeks (SURMOUNT-1), and semaglutide ~14.9% at 68 weeks (STEP-1) [1][11][12]. The triple-agonist mechanism adds an energy-expenditure component the other two lack, but the comparison is suggestive, not definitive.
Dysesthesia — tingling or altered skin sensation — showed up at Phase 3 scale: 20.9% at 12 mg and 8.8% at 9 mg in the TRIUMPH-4 topline, against 0.7% on placebo, and Lilly reports the events were generally mild [13]. The full results await peer-reviewed publication.
Editorial note: Informational only — not medical advice. Retatrutide is an investigational drug not approved by the FDA, EMA, or any other major regulator; the doses described come from clinical trials and are not a prescribing recommendation. Decisions about weight management or diabetes treatment should be made with a licensed healthcare provider familiar with your medical history. See our methodology. § 16 / References 1. Jastreboff AM, et al. Triple–hormone-receptor agonist retatrutide for obesity — a Phase 2 trial (NCT04881760). N Engl J Med 2023. PMID 37366315. (Tier A — RCT) https://pubmed.ncbi.nlm.nih.gov/37366315/ 2. Rosenstock J, et al. Retatrutide in type 2 diabetes — a Phase 2 trial. Lancet 2023. PMID 37385280. (Tier A — RCT) https://pubmed.ncbi.nlm.nih.gov/37385280/ 3. Coskun T, et al. LY3437943 (retatrutide) — GIP/GLP-1/glucagon triple-agonist pharmacology. Cell Metabolism 2022. (Tier A — preclinical, peer-reviewed) https://pubmed.ncbi.nlm.nih.gov/35914514/ 4. Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline) — news release. (Tier A — company disclosure) https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html 5. ClinicalTrials.gov. TRIUMPH-1 — retatrutide Phase 3 in obesity/overweight (NCT05929066; completed April 2026; n=2,335). (Tier A — trial registry) https://clinicaltrials.gov/study/NCT05929066 6. Eli Lilly. Retatrutide demonstrated significant A1C and weight reductions in first Phase 3 type 2 diabetes trial (TRANSCEND-T2D-1 topline, March 19, 2026) — news release. (Tier A — company disclosure) https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html 7. ClinicalTrials.gov. TRANSCEND-T2D-1 — retatrutide Phase 3 in type 2 diabetes (NCT06354660). (Tier A — trial registry) https://clinicaltrials.gov/study/NCT06354660 8. ClinicalTrials.gov. TRIUMPH-4 — retatrutide Phase 3 in obesity with knee osteoarthritis (NCT05931367; completed November 2025; n=445). (Tier A — trial registry) https://clinicaltrials.gov/study/NCT05931367 9. Giblin K, et al. TRIUMPH Phase 3 program — trial design. Diabetes Obes Metab 2026. PMID 41090431. (Tier A — peer-reviewed) https://pubmed.ncbi.nlm.nih.gov/41090431/ 10. Network meta-analysis of retatrutide vs tirzepatide adverse-event frequency. PMC12544991. (Tier B — network meta-analysis, conference abstract) https://pmc.ncbi.nlm.nih.gov/articles/PMC12544991 11. Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT-1). N Engl J Med 2022. (Tier A — RCT) https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 12. Wilding JPH, et al. Once-weekly semaglutide 2.4 mg in overweight or obesity (STEP-1). N Engl J Med 2021. (Tier A — RCT) https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 13. Eli Lilly TRIUMPH-4 Phase 3 topline (December 2025), as reported through secondary coverage — weight-loss, liver-fat, and dysesthesia figures pending peer-reviewed publication. (Tier C — topline, not yet peer-reviewed) 14. Retatrutide Phase 2 body-composition substudy (type 2 diabetes). PMID 40609566. (Tier B — substudy) https://pubmed.ncbi.nlm.nih.gov/40609566/ --- Editorial note: Informational only — not medical advice. Retatrutide is an investigational drug: it is not approved by the FDA for any use, it is not legally available by prescription or from a compounding pharmacy, and anything sold under the name outside a clinical trial is unverified. Some figures on this page come from company topline announcements that have not yet been peer-reviewed. Decisions about peptide therapy should be made with a licensed healthcare provider familiar with your medical history. See our methodology. Last reviewed July 2026.